Dupixent (dupilumab) is a widely prescribed biologic medication used for conditions including eczema and asthma. On September 15, the FDA announced a formal investigation into Dupixent after receiving more than 300 reports of cutaneous T-cell lymphoma (CTCL), a rare form of blood cancer that can affect the skin. The agency is evaluating whether new cancer warnings should be added to the drug’s label.
Lawsuits against manufacturers Sanofi and Regeneron allege the companies failed to warn that Dupixent might trigger or disguise CTCL, delaying proper cancer diagnoses. In October 2025, the first Dupixent wrongful death lawsuit was filed, involving a Tennessee woman who died from T-cell lymphoma months after beginning Dupixent injections, with her family alleging the drug triggered or accelerated the cancer and that patients and doctors were not warned of the risk.
Why the “disguise” allegation matters
One of the more serious aspects of these claims is the allegation that Dupixent may not only trigger CTCL but mask it, since early CTCL can resemble the skin conditions Dupixent treats, potentially delaying diagnosis of a cancer where early detection matters.
Who may have a claim
Patients who used Dupixent as prescribed and were later diagnosed with T-cell lymphoma, especially cutaneous T-cell lymphoma, may have a claim. Families who lost a loved one to CTCL following Dupixent use may have a wrongful death claim.
Talk to us, at no cost
If you or a loved one was diagnosed with T-cell lymphoma after using Dupixent, Pisanchyn Law Firm offers a free, confidential case review, and we do not charge a fee unless we win. Call 1-800-444-5309. This page is part of our mass tort litigation practice.
Frequently Asked Questions
What is the FDA investigating about Dupixent? The FDA announced a formal review after receiving more than 300 reports of cutaneous T-cell lymphoma in Dupixent users, and is evaluating whether new cancer warnings should be added to the label.
What is cutaneous T-cell lymphoma? CTCL is a rare form of blood cancer that affects the skin, and in its early stages it can resemble common skin conditions, including the ones Dupixent is prescribed to treat.
Should I stop taking Dupixent? Do not stop or change any medication without talking to your doctor. A legal claim and your medical treatment decisions are separate matters.
This page is for general informational purposes and does not constitute legal or medical advice. Reading it does not create an attorney-client relationship.
